QuidelOrtho Corp. Stock
€25.40
Your prediction
QuidelOrtho Corp. Stock
Pros and Cons of QuidelOrtho Corp. in the next few years
Pros
Cons
Performance of QuidelOrtho Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 3.250% | 4.098% | -2.308% | -13.014% | -39.524% | -72.718% | -87.426% |
Veeva Systems A | -0.420% | -0.208% | -1.684% | 40.658% | 17.815% | 22.280% | 11.245% |
Thermo Fisher Scientific Inc. | 1.370% | 2.881% | 4.633% | -27.028% | -27.416% | -31.028% | 11.318% |
Waters Corp. | -0.860% | -0.234% | -0.766% | 12.618% | -16.170% | 0.931% | 85.155% |
Comments
News

QuidelOrtho to Participate in Upcoming Investor Conferences
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine

QuidelOrtho Reports First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and

QuidelOrtho to Report First Quarter 2025 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and